[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100552948":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":43,"centralContacts":47,"locations":53,"responsibleParty":70,"collaborators":51,"id":72,"slug":73,"hasResults":74,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":51,"eligibilityCriteria":78,"healthyVolunteers":74,"sex":79,"minAge":80,"maxAge":81,"enrollmentInfo":82,"targetDuration":51,"studyType":85,"phases":86,"briefSummary":88,"conditions":89,"keywords":92,"overallStatus":55,"whyStopped":51,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},{"fullName":5,"class":6},"Mackay Memorial Hospital","OTHER",[8,14,20],{"label":9,"type":10,"description":11,"interventionNames":12},"Solifenacin and mirabegron","ACTIVE_COMPARATOR","Solifenacin 5mg and Mirabegron 25mg",[13],"Drug: Combined pharmacotherapy with Solifenacin and Mirabegron",{"label":15,"type":16,"description":17,"interventionNames":18},"Solifenacin with vaginal estrogen cream","EXPERIMENTAL","Solifenacin 5mg once per day with vaginal conjugated equine estrogen (CEE) 0.625 mg twice a week.",[19],"Drug: Solifenacin with vaginal estrogen cream",{"label":21,"type":16,"description":22,"interventionNames":23},"Mirabegron with vaginal estrogen cream","Mirabegron 25mg once per day with vaginal conjugated equine estrogen (CEE) 0.625 mg twice a week.",[24],"Drug: Mirabegron with vaginal estrogen cream",[26,33,38],{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"DRUG","Combined pharmacotherapy with Solifenacin and Mirabegron","Solifenacin (5mg) is anticholinergic and Mirabegron (25mg) is a beta-3 adrenergic agonist.",[9],[32],"Vesicare and Betmiga",{"type":27,"name":15,"description":34,"armGroupLabels":35,"otherNames":36},"Solifenacin (5mg) is anticholinergic. Premarin, vaginal conjugated equine estrogen vaginal cream (0.625 mg).",[15],[37],"Vesicare and Premarin",{"type":27,"name":21,"description":39,"armGroupLabels":40,"otherNames":41},"Mirabegron (25mg) is a beta-3 adrenergic agonist. Premarin, vaginal conjugated equine estrogen vaginal cream (0.625 mg).",[21],[42],"Betmiga and Premarin",[44],{"name":45,"affiliation":5,"role":46},"Hui-Hsuan Lau, MD","PRINCIPAL_INVESTIGATOR",[48],{"name":45,"role":49,"phone":50,"phoneExt":51,"email":52},"CONTACT","+886-2-25433535",null,"huihsuan1220@gmail.com",[54],{"facility":5,"status":55,"city":56,"state":51,"zip":51,"country":57,"countryCode":58,"cosmosGeoPoint":59,"geoPoint":64,"contacts":65},"RECRUITING","Taipei","Taiwan","TW",{"type":60,"coordinates":61},"Point",[62,63],121.52639,25.05306,{"lat":63,"lon":62},[66],{"name":67,"role":49,"phone":68,"phoneExt":51,"email":69},"Jiun Chyi Hwang, MD","+886-2-2543-3535","jiun1989@gmail.com",{"type":46,"investigatorFullName":45,"investigatorTitle":71,"investigatorAffiliation":5,"oldNameTitle":51,"oldOrganization":51},"Head of urogynecology, Associate Professor","100552948","phase-4-efficacy-of-solifenacin-or-mirabegron-with-local-estrogen-versus-combination-pharmacotherapy-for-overactive-bladder-100552948",false,"NCT06479720","Efficacy of Solifenacin or Mirabegron With Local Estrogen Versus Combination Pharmacotherapy for Overactive Bladder","Efficacy and Safety of Solifenacin or Mirabegron With Local Estrogen Versus Combination Treatment With Mirabegron and Solifenacin for Refractory Overactive Bladder","Inclusion Criteria:\n\n* Patients with detrusor overactivity which defined as a urodynamic observation characterized by involuntary detrusor contractions during the filling phase. Those who were refractory to monotherapy with anti-muscarinics were enrolled for prospective study.\n\nExclusion Criteria:\n\n* Postvoid urine retention before treatment\n* Women who had medical illness and contraindication for using solifenacin and mirabegron, such as narrow-angle glaucoma and hypertension\n* Concerns for using estrogen include: Women with history of cerebrovascular disease; thromboembolic disorders; gallbladder disease; known or suspected breast carcinoma; estrogen-dependent neoplasm or undiagnosed abnormal genital bleeding.","FEMALE","40 Years","90 Years",{"count":83,"type":84},300,"ESTIMATED","INTERVENTIONAL",[87],"PHASE4","To investigates the effects of solifenacin or mirabegron with local estrogen versus combination treatment with solifenacin and mirabegron in women with overactive bladder",[90,91],"Effect of Drug","Urinary Bladder, Overactive",[93,94,95,96],"Detrusor overactivity","Combined pharmacotherapy","Estrogens","Effectiveness","2025-05-06",{"date":99,"type":100},"2025-05-09","ACTUAL",{"date":102,"type":100},"2022-06-16",{"date":104,"type":84},"2026-12-31",{"name":5,"class":6},1]